Product Updates

August 27, 2025 – Vetion Pharmaceuticals, a pioneer in metabolic disease therapeutics, announces that its Tirzepatide injection has entered the World Health Organization (WHO) International Quality Prequalification (PQ) review phase. This critical step positions Vetion to supply high-quality, cost-effective Tirzepatide to low- and middle-income countries (LMICs), addressing urgent global needs in diabetes and obesity management. […]

Vetion® Semaglutide Oral Tablets Obtain Thai FDA Marketing Authorization, Expanding Global Access to Affordable GLP-1 Therapy August 26, 2025 – Vetion Pharmaceuticals, a leader in metabolic disease therapeutics, is proud to announce that its semaglutide oral tablets have received marketing authorization from the Thai Food and Drug Administration (Thai FDA). This milestone enables Vetion to